medigraphic.com
ISSN 0138-7103 (Print)

2016, Number S1

<< Back Next >>

Revista del Hospital Psiquiátrico de La Habana 2016; 13 (S1)

Most relevant knowledge: emerging drugs

Lajús BG

Language: Spanish
References: 27
Page:
PDF size: 96.98 Kb.


ABSTRACT

Introduction: Emerging drugs are added to the global tragedy of drugs with a growing trend of supply and demand, of which Cuba is not exempt.
Objective: To increase the relevant knowledge of emerging drugs, for which an analysis of certain characteristics that has taken this phenomenon in recent years, and the conditions that favor its production, consumption, distribution, proliferation and engagement was performed in populations each younger time.
Methods: For this we searched the Cochrane Library, MEDLINE, EMBASE, PsyclNFO, EBSCO, HINARI, Dissertation Abstracts and articles identified in their bibliographies, in addition to individual searches of MEDLINE of authors who have reported information regarding the emerging drug consumption in the last five years.
Conclusions: The line between legal and illegal drugs becomes increasingly tenuous. The continuous updating of emerging drugs, knowledge of the limitations in the analytical determinations and clinical suspicion, are the only weapons to monitor the changing world of these substances, which become a serious social and health problem. For its development, commercialization and availability, there is no doubt that we are facing the emergence of an innovative market and extremely dynamic, highly accessible, globalized, sophisticated and very attractive to young people, favoring large international drug mafias for the great benefits economic derived from illegal trade in a globalized and neoliberal world.


REFERENCES

  1. Lajús G. Drogas, Adictos, Familia y Sociedad. Caracas, Venezuela: Editora del Ministerio del Poder Popular para la Comunicación y la Información. Colección “ANÁLISIS”; 2008.

  2. Lajús G. Documento Adjunto. Tesis Presentada en Opción del Grado Científico de Doctor en Ciencias Médicas. La Habana; 2010.

  3. Observatorio Europeo de las drogas y las Toxicomanías. Informe anual 2011: el problema de la drogodependencia en Europa. Luxemburgo: Oficina de publicaciones de la Unión Europea, 2011; 106-107 [consultado 22 Feb 2015]. Disponible en: http://www.emcdda.europa.eu/attachements.cfm/ att_120104_ES_EMCDDA_AR2010_ES.pdf.

  4. Griffith SP, Lopez D, Sedefov R, Gallegos A, Hughes B, Noor A, et al. Khat use and monitoring drug use in Europe: the current situation and issues for the future. J Ethnopharmacol 2010; 132: 578-83.

  5. Burillo-Putze G, Balanzó X. Desmontando clichés sobre inmigración y salud. AnSistSanitNavar 2010; 33:127-31.

  6. Naciones Unidas. Oficina contra la Droga y el Delito. Informe Mundial sobre las Drogas; 2012.

  7. Council Decision of 2 December 2010 on submitting 4-methylmethcathinone (mephedrone) to control measures. OfficialJournal of the European Union [consultado 22 Feb 2015]. Disponible enhttp://www.emcdda.europa.eu/attachements.cfm/att_121058_EN_Council_Decision_2 010_759_EU_2_December_2010.pdf

  8. Lajús G. Las Nuevas Drogas en Latinoamérica y el Caribe. Un reto para las Ciencias y para los Órganos de Enfrentamiento, La Habana, Cuba; 2015 (En Prensa).

  9. Winstock A, Mitcheson l, Marsden J. Mephedrone: still available and twice the price. Lancet 2010; 376: 1537.

  10. Ministerio de la Presidencia. Resolución de 23 de diciembre de 2010, de la Presidencia del Consejo Superior de Deportes, por la que se aprueba la lista de sustancias y métodos prohibidos en el deporte. Boletín Oficial del Estado 317, España; 2010.

  11. Schifano F, Albanese A, Fergus S, Stair J L, Deluca P, Corazza O, et al. Mephedrone (4- methylmethcathinone; "meow meow"): chemical, pharmacological and clinical issues. Psychopharmacology 2011; 214: 593-602.

  12. Carhart-Harris R L, King L A, Nutt D J. A web-based survey on mephedrone. Drug Alcoh Depend 2011; 118: 19-22.

  13. Martínez-Clemente J, Escubedo E, Pubill D, Camarasa J. Interaction of mephedrone with dopamine and serotonin targets in rats. EurNeurpsychopharmacol 2012; 22: 231-6.

  14. Martínez-Morillo M, Depreux N, Tudela P, Juncà J. Khat, mefedrona y dolor torácico. MedClin 2011; 137: 708-14.

  15. Brunt T M, Poortman A, Niesink R, van den Brink W. Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol 2011; 25: 1543-7.

  16. Ramos L, Lodi S, Bhatt P, Reitz A B, Tallarida C, Raffa RB, et al. Mephedrone ("bath salt") pharmacology: insights from invertebrates. Neuroscience. (Enprensa); 2012.

  17. McElrath K, O'Neill C. Experiencies with mephedronepre- and post-legislative controls: Perceptions ofsafety and sources of supply. Int J Drug Policy 2011; 22: 120-7.

  18. Meng H, Cao J, Kang J, Ying X, Ji J, Reynolds W, et al. Mephedrone, a new designer drug of abuse, produces acute hemodynamic effects in the rat. ToxicolLett 2012; 208: 62-8.

  19. Newcombe R. Mephedrone: The use of mephedrone (M-Cat, Mewo) in Middlesborough. Manchester: Lifeline Publications; 2009.

  20. Wood D M, Dargan P I. Mephedrone (4-methylmethcathinone): What is new in our understanding of its use and toxicity? ProgNeuropsychopharmacolBiol Psychiatry. (EnPrensa), 2012.

  21. Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg, et al. Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats. Br J Pharmacol 2011; 164: 1949- 58.

  22. Morgan JP. Designer Drugs, en Substance Abuse, pág. 264-9. 3rd. Ed. Williams & Wilkins 1997.

  23. Grob C, Poland R. MDMA, en Substance Abuse, pág 269-276. 3rd Ed. Williams & Wilkins 1997.

  24. de Boer D, Bosman I J, Hidvegi E, Manzoni C, Benko A A, dos Reys LJ, et al. Piperazinelike compounds: a new group of designer drugs-of-abuse on the European market. Forensic SciInt 2001; 121:47-56.

  25. Winstock AR, Mitcheson LR, Deluca P, Davey Z, Corazza O, Schifano F. Mephedrone, new kid for the chop? Addiction 2011; 106: 154-61

  26. EMCDDA (European Monitoring Centre for Drugs and Drug Addiction). Selected Issue 2010. Problem amphetamine and methamphetamine use in Europe. 2010, Lisbon. Disponible en:www.emcdda.europa.eu/publications/selectedissues/ problemamphetamine. Consultado 16 de Febrero 2015.

  27. JIFE (Junta Internacional de Fiscalización de Estupefacientes). Informe 2010 [consultado 13 Ene 2015]. Disponible en: www.incb.org/incb/es/annual_report.html.




2020     |     www.medigraphic.com